MedTrace Logo

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-04-10

No results posted yet for this study

Summary

Rationale: Dotarem provides superior enhancement characteristics compared to other GBCA in fMRU

Specific Aims: Compare enhancement characteristics of Dotarem to other GBCAs in the kidneys used in fMRU

Primary Objectives: Review functional analysis curves and data of fMRU studies and determine enhancement characteristics in the kidneys of the three GBCAs (Dotarem, Gadovist, Magnevist)

Conditions

  • Magnetic Resonance Imaging Contrast Agents

Interventions

DRUG

Magnevist

GBCA enhancement

DRUG

Dotarem

GBCA enhancement

DRUG

Gadovist

GBCA enhancement

Sponsors & Collaborators

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-07-01
Primary Completion
2019-04-01
Completion
2019-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03910114 on ClinicalTrials.gov